Avalo Therapeutics Inc (AVTX) — Strategic Asset Allocation Index
Avalo Therapeutics Inc (AVTX) has a Strategic Asset Allocation Index of 41.1% as of March 2022. Strategic assets (PP&E of $2.60 Million plus long-term investments of $-) total $2.60 Million, measured against net assets of $6.34 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see market value of Avalo Therapeutics Inc.
SAAI
Strategic Assets
PP&E
Net Assets
Avalo Therapeutics Inc Strategic Asset Allocation Index (2017–2021)
This chart shows how Avalo Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2017 to 2021. As of March 2022, the index stands at 41.1%, representing strategic assets of $2.60 Million against net assets of $6.34 Million USD. See debt-free asset ratio of Avalo Therapeutics Inc to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Avalo Therapeutics Inc (2017–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Avalo Therapeutics Inc from 2017 to 2021, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore Avalo Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 11.7% | $2.69 Million | $2.69 Million | $- | $23.08 Million | ▲ +5.1 pp |
| 2020 | 6.5% | $1.61 Million | $1.61 Million | $- | $24.56 Million | ▼ -0.4 pp |
| 2019 | 6.9% | $1.45 Million | $1.45 Million | $- | $21.00 Million | ▲ +4.1 pp |
| 2018 | 2.8% | $586.51K | $586.51K | $- | $20.91 Million | ▲ +2.6 pp |
| 2017 | 0.2% | $44.61K | $44.61K | $- | $27.86 Million | — |